14 October 2014: GW Pharmaceuticals plc announced new physician reports of efficacy and safety associated with the Epidiolex® “expanded access” studies.

Physician reports of efficacy and safety data have been made available on 58 children and young adults with treatment-resistant epilepsy who have been treated with GW’s investigational cannabidiol (CBD) product candidate, Epidiolex, for a period of at least 12 weeks. This includes 27 patients on whom data was reported in June 2014 and an additional 31 patients on whom data has recently been made available to the Company. In addition, of the 58 total patients, 40 patients have been treated for at least 16 weeks and data has been available for this time period also. These data are from three hospital sites in the United States and were generated under expanded access Investigational New Drug applications (INDs) authorized by the U.S. Food and Drug Administration (FDA). In addition, physician reports of safety data were made available on 151 patients (58 patients with 12 weeks treatment effect data plus 93 additional patients for whom 12 week treatment effect data is not yet available).

14 October 2014: The Phase 2a pilot trial was a 10-week randomized, double-blind, placebo controlled study of GWP42003 extract, which features Cannabidiol (CBD) as the primary cannabinoid and which also contains Tetrahyrdocannabinol (THC) and other cannabinoid and non-cannabinoid components. The trial included 60 adult patients with ulcerative colitis who had not been able to gain remission from the condition despite first line treatment with salicylates, and in some cases immunosuppressive therapy.

On August 29, 2013, Corey Hunt, his girlfriend and her family stood around her mother’s hospital bed as the doctors overdosed her on morphine and she passed away. She had been fighting breast cancer and lost. Hunt was frustrated and began searching online for cancer cures.

“I knew there had to be something better out there and we found it. It was cannabis,” he says.

October 10, 2014 | Israeli researchers will soon begin evaluating the anti-tumor effects of cannabidiol, a nonpsychotropic cannabinoid, in patients with cancer.

Researchers at the Hassadah Medical Center in Jerusalem have announced their intent to conduct a Phase II clinical trial to assess the impact of CBD as single treatment among cancer patients. Only patients who have exhausted conventional anti-cancer treatments will be eligible to participate in the study. Once enrolled in the trial, participants will receive CBD for a period of eight weeks.

Activation of the body’s cannabinoid receptors – which is done naturally through the consumption of cannabis – may promote bone formation and reduce bone dissolution, according to a study published this month in the journal Molecular and Cellular Biochemistry, and published online by the U.S. National Institute of Health.

“The type-2 cannabinoid receptor (CB2) is expressed in osteoblasts and plays a role in bone metabolism through regulation on bone mass and bone turnover”, begins the study’s abstract; “but the functional importance of CB2 in osteoblasts under Titanium (Ti) stimulation is incompletely understood.”

Cannabis, and the cannabinoid compounds found within it, has been shown through a large amount of scientific, peer-reviewed research to be effective at treating a wide variety of cancers, ranging from brain cancer to colon cancer. Below is a list of over 60 studies that demonstrate the vast anti-cancer properties of cannabis.

A new study published by the Oxford journal Carcinogenesis, and published online by the U.S. National Institute of Health, has found that the cannabis compound cannabigerol can prevent the progression of cancer cells formed in the colon.

Ribeirão Preto, Brazil: The administration of cannabidiol (CBD), a nonpsychotropic cannabinoid, is associated with improved quality of life in patients with Parkinson's disease, according clinical trial data published online ahead of print in the Journal of Psychopharmacology.

Investigators at the University of São Paulo in Brazil assessed the efficacy of CBD versus placebo in 21 subjects with Parkinson's. Authors reported that the administration of 300 mg doses of CBD per day was associated with "significantly different mean total scores" in subjects' well-being and quality of life compared to placebo.

The presence of tetrahydrocannabinol (THC) in the system is associated with increased survival rates in those who experience traumatic brain injury (TBI), according to a new study published in the American Journal of Surgery.

“Traumatic brain injury (TBI) is associated with significant morbidity and mortality”, says Dr. Binh Minh Nguyen, the study’s lead author. “Several studies have demonstrated neuroprotective effects of cannabinoids. The objective of this study was to establish a relationship between the presence of a positive toxicology screen for tetrahydrocannabinol (THC) and mortality after TBI.”

Earlier this month, an Israeli startup, Syqe Medical Ltd., announced its development of a tiny inhaler that will allow patients new to medicinal marijuana to reap the drug's various benefits, without ever having to get high.

If you are looking for good quality seed to grow your own medicine at home, then check out those guys from Royal Queen Seeds. With more than 2 decades of experience they ship their medical cannabis seeds world wide and guarantee top quality for the best price. Award winners shipped stealth! What more do you need?